Midatech will be presenting interim data from its ongoing Phase I trial assessing lead asset MTX110 in diffuse intrinsic pontine glioma (DIPG) at the upcoming International Symposium on Pediatric Neuro-Oncology (ISPNO). The study is being conducted at the Columbia University Medical Center (CUMC) and the presentation will discuss preliminary results (safety signals) for seven of the 10 study participants. A highlight of this study is the use of an implantable continuous flow device to deliver MT ....
13 Jun 2022
Midatech Pharma - Interim DIPG data to be presented at ISPNO
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Midatech Pharma - Interim DIPG data to be presented at ISPNO
- Published:
13 Jun 2022 -
Author:
Jyoti Prakash -
Pages:
2
Midatech will be presenting interim data from its ongoing Phase I trial assessing lead asset MTX110 in diffuse intrinsic pontine glioma (DIPG) at the upcoming International Symposium on Pediatric Neuro-Oncology (ISPNO). The study is being conducted at the Columbia University Medical Center (CUMC) and the presentation will discuss preliminary results (safety signals) for seven of the 10 study participants. A highlight of this study is the use of an implantable continuous flow device to deliver MT ....